JWCAR201

BIOLOGICAL2 trials

Sponsors

Fudan University, RenJi Hospital

Conditions

Autoimmune DiseasesB-cell TumorsDiffuse Large B Cell LymphomaLarge B-cell LymphomaLupus Erythematosus, Systemic

Phase 1

An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

RecruitingNCT06517004

Fudan UniversityDiffuse Large B Cell Lymphoma

Start: 2024-07-18End: 2027-08-31Target: 9Updated: 2024-07-24

JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases

Not yet recruitingNCT06567080

RenJi HospitalAutoimmune Diseases, B-cell Tumors, Large B-cell Lymphoma +1

Start: 2024-09-30End: 2027-03-31Target: 15Updated: 2024-08-22

Related Papers

Preliminary safety and efficacy of anti-CD19/CD20 bispecific CAR-T cell therapy (JWCAR201) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: Results from an ongoing phase I study

Blood2025-11-03